Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.65 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PYGL | P06737 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19850582 | 0.85 | CNR2 (0.58) | CNR2DRD2TAS1R3TAS1R1GAA | |
| SCHEMBL19837639 | 0.79 | CNR2 (1.00) | CNR2GAAKDM4EALDH1A1MAPK1 | |
| SCHEMBL13753384 | 0.78 | DRD2 (0.68) | DRD2TAS1R3TAS1R1GAAKDM4E | |
| SCHEMBL29949076 | 0.78 | DRD2 (0.68) | DRD2TAS1R3TAS1R1GAAKDM4E | |
| SCHEMBL19837648 | 0.77 | NPC1 (0.48) | CNR2P2RX7KDM4EALDH1A1EPHX2 | |
| SCHEMBL19837646 | 0.76 | CNR2 (0.67) | CNR2P2RX7DRD2GAAKDM4E | |
| SCHEMBL13753482 | 0.75 | DRD2 (0.64) | DRD2TAS1R3TAS1R1GAAKDM4E | |
| SCHEMBL8670236 | 0.74 | CCKAR (0.77) | DRD2TAS1R3TAS1R1GAAKDM4E | |
| SCHEMBL8670229 | 0.74 | CCKAR (0.77) | DRD2TAS1R3TAS1R1GAAKDM4E | |
| SCHEMBL29988822 | 0.74 | CNR2 (0.65) | CNR2GAAKDM4EALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383848-B2 | Indole-based therapeutics | CREIGHTON UNIVERSITY (US) | 2019-08-20 | — | — | US | disclosed |
| US-10383848-B2 | Indole-based therapeutics | CREIGHTON UNIVERSITY (US) | 2019-08-20 | — | — | US | disclosed |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383848-B2 | Indole-based therapeutics | IDO2, IDO1, INMT | CNR2 57/4885P2RX7 4019/4885DRD2 2461/4885 |
| US-20180036283-A1 | INDOLE-BASED THERAPEUTICS | IDO2, IDO1, INMT | CNR2 57/4885P2RX7 4019/4885DRD2 2461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.